PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in...
Transcript of PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in...
![Page 1: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/1.jpg)
![Page 2: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/2.jpg)
![Page 3: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/3.jpg)
![Page 4: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/4.jpg)
https://www.google.com/url?sa=i&url=https%3A%2F%2Fgiphy.com%2Fexplore%2Fyes-sure&psig=AOvVaw0nbJh_ddNLFA6QsHpj2pBT&ust=1596813504445000&source=images&cd=vfe&ved=0CAIQjRxqFwoTCIjE1IDwhusCFQAAAAAdAAAAABAD
![Page 5: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/5.jpg)
So, What Is Next?
• This recommendation made before EXTEND-IA TNK fully reported
• Community experiences being reported
• As Dr. Asimos mentioned, numerous trials underway
• What will happen after they report?
TNK?
![Page 6: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/6.jpg)
If Robustly POSITIVE
• AHA could issue a Practice / Science Advisory since new guidelines not in the near future
• Genentech may go for an indication if there is enough U.S. based data and it is veryrobust; may increase the price
• Community adoption will accelerate
![Page 7: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/7.jpg)
If TEPID, NEUTRAL or NON-INFERIOR
• No guideline update since it is already IIb
• Genentech will do nothing
• Alteplase will remain SOC and tenecteplase adoption will be sporadic
![Page 8: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/8.jpg)
If NEGATIVE
• AHA could issue a Practice / Science Advisory since new guidelines not in the near future if there is major harm
• Genentech will do nothing
• Community adoption will cease
![Page 9: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/9.jpg)
Data Table From 2019 Guidelines
![Page 10: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/10.jpg)
![Page 11: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/11.jpg)
![Page 12: PowerPoint Presentation · more effective than alteplase In achieving recanalization of a LVO in patients who were candidates for both IV thrombolysis and EVT .Tenecteplase was also](https://reader030.fdocuments.us/reader030/viewer/2022011922/6047667da032f94ee41f7838/html5/thumbnails/12.jpg)